WID’s Tom Turng envisions a future in which surgeons can order mass-produced artificial blood vessels that arrive ready to use in bypass surgeries.
WID seeks to add to its roster of excellent faculty with two new hires in emerging cutting-edge fields.
WID’s new hubs—Data Science, Multi-Omics, and Illuminating Discovery—represent a new path forward for collaborative research projects and fields.
A paper published in eLife this week by an interdisciplinary team at WID describes new methods for reproducibly manufacturing brain and spinal cord organoids with strict control over morphogenic and developmental processes.
A second WID-led team joins NIH’s Somatic Cell Genome Editing Consortium with a grant to study new methods of delivering the CRISPR/Cas9 system to the brain.
Investigators from WID are among the recipients of the latest round of UW2020 awards.
One of the UW Carbone Cancer Center members presenting is WID’s Peter Lewis. His work focuses on how genes are turned on and off during embryonic development, and how misregulation in those genes can lead to some childhood cancers.
WID researcher Shaoqin Sarah Gong is working to more safely deliver a variety of drugs to treat cancer, heart disease and even blindness.
Biomedical engineering professor and Discovery Fellow Kristyn Masters and colleagues identified the early stages of a process that may eventually cause aortic stenosis, a severe narrowing of the aortic valve that reduces blood flow to the body and weakens the heart.
In August 2017, Randolph Ashton received almost $800,000 from the National Institute of Neurological Disorders and Stroke, part of NIH, to continue a five-year research study of Lou Gehrig’s disease (amyotrophic lateral sclerosis, or ALS), after successfully completing its first phase.
The National Science Foundation has awarded nearly $20 million to a consortium of universities to support a new engineering research center that will develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells. Several WID investigators are collaborators on the project.